---
schema_version: "secwatch.filing_event.v1"
accession: "0000872589-26-000023"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2026-07-30T10:48:32+00:00"
generated_at: "2026-07-30T10:50:06.807416+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q2 2026 revenue up 17% to $4.3B; non-GAAP EPS $14.29 beats; Dupixent sales up 38%

## Summary
- Total revenues $4.291B (+17% YoY); GAAP EPS $12.23 (incl. $1.02 IPR&D charge); non-GAAP EPS $14.29 (+11%).
- Dupixent global net sales (Sanofi) up 38% to $6.0B; EYLEA HD U.S. net sales up 52% to $596M; Libtayo global up 30% to $489M.
- Sanofi Development Balance fully repaid; collaboration profits to step up in Q3. Guidance raised: GAAP gross margin 78-79% (prior 77-78%).
- Cemdisiran NDA accepted for gMG with priority review; FDA target action date Nov 2026.
- Share repurchases $1.2B in Q2; $2.0B in H1; dividend $0.94/share declared.

## SEC filing metadata
- accession: 0000872589-26-000023
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2026-07-30T10:48:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/0000872589-26-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/regn-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000872589-26-000023
- JSON: https://secwatch.observer/filing/0000872589-26-000023.json
- Plain text: https://secwatch.observer/filing/0000872589-26-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.